BioCity Biopharma Unveils Positive Late-Breaking Results from 2-SUCCEED Trial of SC0062 for IgA Nephropathy at ASN Kidney Week 2024

05 November 2024 | Tuesday | News

The Phase II trial demonstrates SC0062’s potential to reduce proteinuria in high-risk IgAN patients, offering promising insights into its efficacy and safety as a targeted treatment.
Picture Courtesy | Public Domain

Picture Courtesy | Public Domain

BioCity Biopharma (BioCity) announced late-breaking results of the 2-SUCCEED clinical trial of SC0062, a selective endothelin receptor type A (ETA) antagonist, for the treatment of IgA Nephropathy (IgAN). These results were presented at the Oral Abstract Session of American Society of Nephrology (ASN) Kidney Week 2024 and published simultaneously in the Journal of the American Society of Nephrology (JASN), a leading kidney journal worldwide.  

The 2-SUCCEED trial was designed as a multi-center, randomized, double-blind, placebo-controlled, two-cohort (IgAN and diabetic kidney disease [DKD]), Phase II study. The principal objective of the IgAN cohort was to evaluate the efficacy, safety, and optimal dose of SC0062 compared to placebo to determine SC0062's ability to reduce proteinuria in subjects at high risk of disease progression. The study allowed enrolment of subjects who were receiving sodium/glucose cotransporter 2 (SGLT2) inhibitors as a background therapy. Overall, 131 patients were randomized in a 1:1:1:1 ratio to 24 weeks of treatment with either SC0062 doses of 5 mg, 10 mg, or 20 mg or placebo once daily. A similar evaluation of SC0062 in the 2-SUCCEED cohort of subjects with DKD is ongoing. 

The detailed results of the clinical trial can be obtained from the manuscript entitled "The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy: A Randomized Double-Blind Placebo-Controlled Clinical Trial" which was published in JASN(ASN.0000000538, October 26, 2024.).

SC0062 has been granted the Breakthrough Therapy Designation (BTD) by the Chinese regulatory agency National Medical Products Administration (NMPA) for the treatment of IgA Nephropathy with proteinuria.

Dr. Hiddo Lambers Heerspink, a world-renowned expert in clinical trials for the treatment of chronic kidney disease (CKD), who presented the results of SC0062 at ASN, commented "The significant and sustained reduction in urine protein excretion with SC0062, along with its notable safety advantages compared to other treatments, support a larger and long-term clinical trial in subjects with various types of CKD including IgA nephropathy. We look forward to the results of further studies on this drug.

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close